• Oversaw 19% YoY topline growth and record-setting new patient starts for two in-line brands• Led US Brand Planning and securing executive endorsement and buy up funding, with accountability for US tactical execution• Developed personal and non-personal promotional tactics for critical RWE, and partnered with PRC, Medical and Training to lead trainings for the Field Team• Overhauled HCP segmentation and realigned marketing messages and resources, including NPP email journeys and media activations• Delivered innovative, omnichannel initiatives to activate the patient community: first-to-company initiatives include Facebook and Instagram (with comments on), CTV, Jebbit, and TikTok • Implemented an innovative multichannel adherence program that increased patient retention by ~60%• Won the 2021 PM360 Trailblazer “Brand Champion Award” for Metabolic Disorders, the 2022 DTC National “Top 25 Marketer Award”, and led the STRENSIQ Brand team to receive 5 additional award nominations• Managed 3 directs (1 second line), successfully advocated for promotion and excellence awards for my team to support their development and growth

• Led the Monthly Business Review (MBR) process, a cross-functional review with leadership of brand KPIs to generate insights on performance and cross-functional alignment on where adjustments are required• Developed an inside sales program to drive increased disease education among tier 3 targets and free up sales reps to focus on high-impact target conversion• Represented the US on Global workstreams to update the STRENSIQ CCDS, and led the US label update• Overhauled the therapy initiation process resulting in a 20% reduction in first shipment time vs. prior year• Stood up the first-to-Alexion branded Facebook Community, exceeding industry benchmarks with 22% engagement rate, and responsible for driving up to 50% of traffic to brand.com• Led two quantitative, strategic projects for the Wilson Launch and presented the findings to US and Global Commercial and Medical Leadership

• Developed the strategy and led the execution of for a new direct-to-patient marketing program, with budget responsibility for digital marketing initiatives, patient educational events, advocacy group partnerships and point-of-care sales tools• Executed an omni-channel patient testimonial marketing campaign utilizing web, digital, social, local and national PR (Newsweek, WSJ) and sponsored content, presenting status updates to VPs and SVPs during management board • Led web design, content development and digital strategy for DBSandMe.com, Boston Scientific's online resource for patients and their caregivers to learn about DBS as a therapy option for Parkinson's disease• Developed and secured funding for national partnerships with patient advocacy groups providing BSC teams with educational opportunities at patient walks, referral events, and national congresses

• Launched the US Deep Brain Stimulation (DBS) franchise, and led 4 successive product launches in the US and EU• Built award-winning HCP campaign to support launch of novel, Directional DBS System, including corporate home page takeover• Built a bottom-up model of the US DBS implant market using Medicare and private payer claims data and used geotagging to identify key accounts for sales targeting• Partnered with Medical and HEOR to develop and economic value proposition and value in-sell deck for key IDN strategic accounts, and led sales training for roll out to key field reps • Executed an omni-channel marketing campaign utilizing web, digital, social, local and national PR (Newsweek, WSJ) and sponsored content, presenting status updates to VPs and SVPs during management board• Developed a quantitative approach to segment key accounts using procedural, financial, and behavioral inputs, and built visualization dashboard using Tableau, resulting in the “Think Different” Marketing Award

• Built models to forecast global surgical procedure volumes and conducted due diligence on IP landscape for competing technology platforms as part of an opportunity assessment for major endoscope manufacturer, ultimately recommending that the client execute on a >$1B acquisition• Developed a market entry strategy for leading medical devices player, including threat assessment from changing insulin pump reimbursement and disruption by new technologies, and delivered a strategic roadmap for client to become the #3 US player in 3 years• Developed and presented a novel market model for drug delivery devices to BCG’s CEO and deployed this unique strategy in over 20 client engagements, allowing them to simulate how acquisition plays in different product categories are accretive to growth• Built an analytic module in Alteryx platform using Medicare claims data to inform salesforce re-targeting of a major US neurostimulator manufacturer• Co-authored a white paper guiding suppliers on how provider consolidation and the shift to a value-based care delivery impacts the Medical Device commercial model• Drove the development of new strategy work on digitally-enabled respiratory inhalers that directly sold to a major European pharmaceutical client, resulting in $1.6B incremental revenue for the client

• Launched seven new gene therapy products, and developed digital marketing campaigns to boost reach, resulting in a 43% increase in new clients• Re-segmented customer base and developed marketing campaign to drive volume towards highest-margin clients• Performed benchmarking analysis against competitors and raised prices on 4 legacy offerings• Awarded the 2013 Partner in Excellence Award for Individual Achievement in Operational Efficiency by C-level executives in Partners HealthCare

• Negotiated discounted prices with suppliers for consumables, saving the lab up to 68% annually.• Organized and led a team of groups from different departments to renew our organization’s expired radioisotope license with the Mass. Bureau of Environmental Health.

• Developed and wrote a program to record and analyze large streams of data in real-time, enhancing our knowledge-capture capability.• Presented a research abstract at the 2010 Mechanisms of Anesthesia Conference.• Took on a project that multiple individuals had dismissed as too risky and successfully completed it, resulting in a publication in the journal Molecular Pharmacology.

I was selected from a pool of over 5,000 applicants to participate in the nation's oldest merit-based summer research program at The Jackson Laboratory. I executed an immunohistochemical screen for cell type-specific surface markers in mice with degenerative ocular phenotypes. At the end of the program, I was invited to continue as a paid research associate to clone and study a gene mutated in certain neuromuscular diseases.